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Abstract The objective of this study was to evaluate the
cost-effectiveness of posaconazole versus fluconazole for
the prevention of invasive fungal infections (IFI) in graft-
versus-host disease (GVHD) patients in the Netherlands. A
decision analytic model was developed based on a double-
blind randomized trial that compared posaconazole with
fluconazole antifungal prophylaxis in recipients of allogene-
ic HSCT with GVHD who were receiving immunosuppres-
sive therapy (Ullmann et al., N Engl J Med 356:335–347,
2007). Clinical events were modeled with chance nodes
reflecting probabilities of IFIs, IFI-related death, and death
from other causes. Data on life expectancy, quality-of-life,
medical resource consumption, and costs were obtained
from the literature. The total cost with posaconazole
amounted to €9,428 (95% uncertainty interval €7,743–
11,388), which is €4,566 (€2,460–6,854) more than those
with fluconazole. Posaconazole prophylaxis resulted in 0.17
(0.02–0.36) quality adjusted life year (QALY) gained
compared to fluconazole prophylaxis, corresponding to an
incremental cost effectiveness ratio (ICER) of €26,225 per
QALY gained. A scenario analysis demonstrated that at an
increased background IFI risk (from 9% to 15%) the ICER
was €13,462 per QALY. Given the underlying data and
assumptions, posaconazole prophylaxis is expected to be
cost-effective relative to fluconazole in recipients of
allogeneic HSCT developing GVHD in the Netherlands.
The cost-effectiveness of posaconazole depends on the IFI
risk, which can vary by hospital.
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Introduction
Over the past two decades, the incidence of invasive fungal
infections (IFI) has been rising [1]. The main risk groups
for IFIs are patients experiencing prolonged, profound
neutropenia following intensive chemotherapy for hemato-
logical malignancies and patients undergoing allogeneic
haematopoietic stem cell transplantation (HSCT) [1]. Graft
failure and graft-versus-host disease (GVHD), as well as
the immunosuppression required for GVHD management,
can exacerbate susceptibility to IFIs in HSCT patients [1].
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Studies have reported invasive fungal infections as the
primary cause of mortality associated with GVHD [2, 3].
Early diagnosis of fungal infections is difficult as nonspe-
cific symptoms (fever) are often the only sign. Furthermore,
antifungal treatment of established IFIs has a high failure
rate (60–70%) for allogeneic HSCT recipients [3, 4] and is
very costly [5]. Hence, prophylaxis of IFIs is often
considered as a valuable treatment strategy for neutropenic
patients.
In the Netherlands, fluconazole is the preferred orally
administered antifungal agent for prophylaxis of IFI.
Prophylaxis with fluconazole reduces morbidity and
mortality among recipients of allogeneic HSCT [6, 7].
One of the limitations of fluconazole is the lack of efficacy
against aspergillus species, which together with Candida
species are the most common causes of IFIs [8–10].
Posaconazole is a new-generation triazole which displays
a broad spectrum of activity [3]. In two randomized
controlled trials (RCT), the prophylactic efficacy relative
to standard azoles was established in recipients of alloge-
neic HSCT [11] as well as in neutropenic patients
undergoing remission–induction chemotherapy for acute
myeloid leukemia (AML) and high-risk myelodysplastic
syndrome (MDS) [12]. Based on these RCTs, posaconazole
is licensed for prophylaxis of IFIs in these patient
populations.
Since controlling the healthcare budget is a major
priority for all healthcare systems, decisions related to
reimbursement or budget allocation will be based not only
on efficacy and safety of the available antifungal agents but
also on the associated costs. Though the acquisition costs
for posaconazole are higher relative to fluconazole,
information on other medical resource consumption related
to the treatment of fungal infections is required for a
complete pharmacoeconomic picture. RCTs are generally
not designed to provide this information. A model-based
health economic study on the other hand is a well-accepted
method to assess the cost-effectiveness of interventions. It
allows for the integration of efficacy and safety data from
clinical trials and medical resource consumption from other
data sources and accounts for the uncertainties that result
from such a combination of information. A recent
economic evaluation demonstrated that posaconazole pro-
phylaxis is expected to be cost-effective compared to
standard azole in neutropenic AML/MDS patients in the
Netherlands [13].
The objective of this study was to estimate the cost-
effectiveness of prophylaxis with posaconazole relative to
fluconazole for the prevention of IFIs in allogeneic HSCT
recipients receiving intensive immunosuppressive therapy
for GVHD in the Netherlands. The analysis encompasses
the payer perspective and was based on the RCT conducted
by Ullmann and colleagues [11].
Methods
Model structure
A decision analytic model was developed (Fig. 1) to
estimate the cost-effectiveness of orally administered
posaconazole (600 mg/day) versus standard fluconazole
(400 mg/day) in patients with GVHD following HSCT
treated with intensive immunosuppressive therapy. In line
with the RCT by Ullmann et al. [11], the average age of
patients was 40 years. Although the trial population
consisted of 65% males, the model assumed an equal
distribution of males and females because for the majority
of source data used in the economic evaluation, only
estimates for the total population (based on about 50%
males and 50% females) were available. Consistent with the
duration of the trial, clinical events during the first 112 days
were modeled with a decision tree consisting of chance
nodes reflecting the probability of a proven or probable IFI
according to international consensus criteria, IFI related
death, and death from other causes associated with
posaconazole and fluconazole (see Fig. 1). The results of
the 112-day trial were extrapolated to lifetime expected
outcomes using a Markov state-transition structure consist-
ing of repeated Markov cycles of 1 month. This allows for
the estimation of the number of life years (LY) and quality
adjusted life years (QALY) among patients that survived
the prophylactic period. It was assumed that patients who
survived an IFI during the prophylactic period displayed a
monthly mortality rate similar to patients who did not
experience an IFI.
With the model, the following outcomes were estimated for
a patient treated with either posaconazole or fluconazole: (1)
probability of an IFI; (2) life expectancy expressed in LYs; (3)
expected QALYs, calculated as the LYs multiplied with the
quality of life (or utility) of the of the underlying condition (i.
e., GVHD); and (4) expected direct costs consisting of
acquisition costs of antifungal drugs and costs of treating an
IFI. In addition to these expected outcomes by treatment,
differences in outcomes with posaconazole relative to
fluconazole were estimated: (5) LYs gained, QALYs gained;
(6) incremental costs; (7) and incremental costs expressed per
LY or QALY gained (i.e., the incremental cost-effectiveness
ratios (ICER)). Since the adverse event rate was similar for
posaconazole and fluconazole in the RCT, costs and con-
sequences due to adverse events were not included in this
cost-effectiveness analysis.
Source data
Source data for the model analysis were obtained from the
literature and validated in two separate consensus meetings
with six Dutch clinical experts (one meeting with four and
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one meeting with two experts) including the co-authors J.J.
W.M.J., E.L., and L.S.
The following data were used in the model (see Table 1):
1. The probability to contract an IFI during the 112-day
period following initiation of prophylaxis with either
posaconazole (5.3%) or fluconazole (9.0%) was
obtained from Ullmann et al. [11].
2. Life years: the life expectancy per treatment arm was
obtained by estimating the survival during as well as
beyond the 112-day prophylactic period. The probability
to survive the 112-day period following initiation of
prophylaxis was estimated using data from Ullmann et al.
[11]. The trial data provided the risk of dying due to an
IFI as well as the probability of dying from other causes.
Parameter Value Uncertainty
range
Distribution used
for probabilistic
sensitivity analysis
Source
Probability of IFI with fluconazole 0.09 0.06;0.12 Beta [11]
Probability of IFI with posaconazole 0.05 0.03;0.08 Beta [11]
Case-fatality of an IFI 0.37 0.23;0.52 Beta [11]
Probability of death from other causes 0.25 0.21;0.28 Beta [11]
Excess mortality after 112 days 0.04 – – [14]
IFI treatment costs € (non-responders) €37,204 €31,621;
€45,301
Gamma [5] personal
communication
Posaconazole treatment durationb 80.3 64.6; 96.0 Gamma [11]
Fluconazole treatment durationa 77.2 62.1; 92.3 Gamma [11]
Utility (quality of life score for
underlying GVHD)
0.9 0.75;1.0 Uniform [16]
Table 1 Model input
parameters for the base-case
scenario along with the
uncertainty distributions
Model input (mean and
uncertainty range); for
scenarios, see “Analysis”
section
aMean values were obtained from
the trial [11] and the low and
high value was obtained by
assuming a standard error of 10%
Fig. 1 Decision analytic model for cost-effectiveness evaluation of posaconazole versus fluconazole for prophylaxis of fungal infections.
* survival beyond 112 days was extended with 1-month Markov cycles (M)
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The reported case fatality for IFI was significantly
different between treatment arms (0.25 and 0.44 for
posaconazole and fluconazole, respectively). However,
since overall mortality was found to be similar between
the two groups, we assumed equal case fatalities for the
base-case analysis. Therefore, case-fatality rates were
pooled for both treatment groups. The probability of
death from other causes did not differ significantly
between treatments either and were assumed to be equal
for both treatment groups as well. The life expectancy
beyond the 112-day period was assumed to follow that of
chronic GVHD patients. Accordingly, a Weibull curve
was fitted through the 10-year survival data of chronic
GVHD patients as reported by Wingard and colleagues
[14]. From this analysis, an annual excess mortality of
4% relative to the standard Dutch population was
observed. Next, this annual excess mortality rate for
GVHD was added to the age-specific death rates for the
general Dutch population obtained from Dutch Life
Tables [15] to estimate survival beyond the prophylactic
period.
3. QALYs were obtained by multiplying the life expectan-
cy in each treatment arm by the utility (or quality of life
score) of the underlying condition. For chronic GVHD, a
mean utility of 0.9 (range 0.75 to 1) was reported [16].
Nietert and colleagues estimated a similar value, for
chronic GVHD [17]. Accordingly, it was assumed that
if GVHD patients survived the 112 days following
initiation of prophylaxis, the utility for chronic GVHD
could be applied.
4. The costs incorporated in the model related to the costs of
prophylaxis and treatment of an IFI. Doses of antifungal
drugs used in the trial were similar to those used in daily
clinical practice in the Netherlands. In the clinical trial,
capsules of fluconazole were used. Since neither guide-
lines nor protocols suggest any preference of using a
specific formulation of fluconazole, the base-case analy-
sis was conducted with the less expensive formulation of
capsules. In a separate scenario analysis, the cost of the
oral suspension was used. To estimate the total cost of
antifungal drug use, the average treatment duration with
the antifungal drugs obtained from the trial was multiplied
with the per-diem drug costs. The cost for posaconazole
(600mg, oral suspension) were €92.86 and for fluconazole
(capsule) €19.60 [18]. An economic evaluation of the
treatment of proven and probable invasive aspergillosis in
the Netherlands by Jansen et al [5] reported expected
costs for treatment with voriconazole, conventional
amphotericin B, or itraconazole (€32,651, €33,616, and
€29,115, respectively). These direct cost estimates
were an average of responders and nonresponders to
initial antifungal treatment and include costs associ-
ated with diagnosis, all antifungal drug treatment
(first and switch treatments), monitoring, side effects,
hospitalization, and outpatient care (for more details,
see Jansen et al. [5]). For the type of patient
considered in the current evaluation, these average
cost estimates for an IFI by Jansen et al. are arguably
an underestimation; the costs associated with treat-
ment of IFIs among patients that received prophylactic
treatment are probably better reflected by the cost
estimates for nonresponders used in the study by
Jansen et al. [5]. An estimate for this subgroup was
obtained by contacting the authors of that study. After
inflating this 2003 estimate to 2006, a cost of €37,204 was
obtained which includes antifungal cost, hospitalization
cost (including ICU stay), monitoring, and treatment of
side effects. This estimate was applied to patients
experiencing an IFI in the base-case scenario. In an
alternative scenario, the average cost for responders and
nonresponders as reported by Jansen et al. was used. All
cost estimates were expressed in euros for the year 2006.
In view of the fact that costs were incurred within the first
year following the start of prophylaxis, discounting on
costs was not applied. For outcomes, an annual discount
rate of 1.5% for effects was applied in accordance with
Dutch pharmacoeconomic guidelines [19].
Analysis
The source data are characterized by uncertainty. To incorpo-
rate this uncertainty in the evaluation, a probabilistic
sensitivity analysis (PSA) was performed (Excel 2003/Visual
basic) to quantify its effect on the model outcomes [20]. The
uncertainty of the input parameters was reflected with a
distribution that defined the probability of a certain value for
the input parameters (Table 1). A random value from these
input distributions was plugged in the model, and the
corresponding expected costs and outcomes were calculated.
This procedure was repeated 1,000 times to obtain uncer-
tainty distributions of the expected outcomes. Each outcome
was presented with a point estimate along with uncertainty
reflected by the 2.5th and 97.5th percentile of the uncertainty
distribution (the 95% uncertainty interval (UI)).
Posaconazole is considered cost-effective relative to
fluconazole when the incremental cost per QALY gained is
below a defined ceiling ratio of cost-effectiveness. For
example, if the maximum willingness-to-pay (WTP) of a
payer is €50,000 per QALY gained, then posaconazole is
considered a cost-effective treatment when posaconazole is
more efficacious and the ICER of posaconazole relative to
fluconazole as estimatedwith themodel is below this €50,000.
Given the uncertainty in the source data and, therefore, the
uncertainty in model estimates of cost-effectiveness, there
is a certain probability that the incremental cost-effectiveness
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ratio is not below the WTP ceiling ratio. The lower the WTP
ceiling ratio, the more difficult it is for a treatment to be
considered cost-effective given its incremental cost-
effectiveness estimate. Acceptability curves were created to
present the probability that posaconazole is cost-effective
relative to fluconazole for different WTP ceiling ratios given
the estimated ICERs and associated uncertainty.
Different scenarios were evaluated with the model. The
base-case scenario was defined by applying the pooled IFI
case fatality, IFI treatment costs of nonresponders, and
fluconazole administered as a capsule. In addition to the
base-case scenario, the following additional scenario
analyses were performed:
1. No discounting of outcomes.
2. Fluconazole administered as oral suspension (400 mg),
€27.89 [18].
3. Instead of the conservatively assumed IFI case fatalities
(equal for both treatments) treatment-specific IFI-
related deaths as observed in the trial was employed
(i.e., 0.25 (0.02–0.48) and 0.44 (0.18–0.70) for pos-
aconazole and fluconazole, respectively) [11].
4. Average IFI treatment costs as reported by Jansen et al.
[5]: €33,279 (€29,211–37,347; 2,006 euros).
5. Ullmann et al. noted that the observed incidence of IFIs
in the trial was lower than those reported in other
studies [11, 21, 22]. Consequently, in a scenario
analysis, a risk of contracting an IFI of 15% was
applied for fluconazole prophylaxis.
Results
Base-case scenario
Prophylaxis with posaconazole compared to fluconazole is
expected to reduce the risk of IFIs with 4% (95% UI 0–8%;
Table 2). With an IFI case fatality of 0.37 and the life
expectancy of the underlying condition, the observed
reduction in IFIs resulted in an increase of 0.19 LYs (95%
UI 0.02–0.39) relative to fluconazole treatment. Taking into
account the utility of the underlying condition, these
differences translated into 0.17 QALYs (95% UI 0.02–
0.36) gained with posaconazole (Table 2).
The expected direct medical costs per patient were
greater with posaconazole than with fluconazole prophy-
laxis. The costs with posaconazole were primarily incurred
during the prophylactic period (79%), whereas the majority
of costs with fluconazole related to treatment of IFIs (69%)
due to unsuccessful prophylaxis (Table 2). The ICER of
posaconazole versus fluconazole is estimated to be €
24,016 per LY gained and €26,225 per QALY gained.
(€4,566; 95% UI €2,460–6,854)
In Fig. 2, the probability that posaconazole is cost-effective
relative to fluconazole is presented for different WTP ratios.
Considering a WTP threshold of €50,000 per QALY, there is
a 79% probability that posaconazole is cost-effective in
comparison to fluconazole.
Alternative scenarios
The results of the alternative scenario analyses are
presented in Table 3. When discounting was discarded,
the incremental QALYs and LYs slightly increased.
Applying treatment-specific case fatalities for IFIs, as
reported by Ullmann et al. [11], almost doubled the
incremental LYs and QALYs gained with posaconazole.
The incremental cost-effectiveness ratio of posaconazole
versus fluconazole decreased to €13,519 per LY gained and
€14,868 per QALY gained. The scenario analysis assuming
a higher IFI risk (15%) resulted in a reduction in
incremental costs of posaconazole versus fluconazole and
also increased incremental LYs and QALYs. For this
scenario, the incremental cost-effectiveness ratio of pos-
Posaconazole mean
(95% UI)
Fluconazole mean
(95% UI)
Difference mean
(95% UI)a
Probability of an IFI 0.05 0.09 −0.04
(0.03;0.08) (0.06;0.12) (−0.08;0.00)
Life expectancy in years 11.66 11.47 0.19
(11.10;12.19) (10.88;12.02) (0.02;0.39)
Quality Adjusted Life Years 10.52 10.35 0.17
(8.83;11.74) (8.67;11.60) (0.02;0.36)
Total treatment cost € 9,428 € 4,861 € 4,566
(7,743;11,388) (3,597;6,243) (2,460;6,854)
% Prophylactic drug costs 79% (€ 7,457) 31% (€ 1,513)
% IFI treatment costs 21% (€ 1,971) 69% (€ 3,348)
Table 2 Expected outcomes
and costs per patient
a The uncertainty range is based
on the 2.5th and 97.5th percentile
of the uncertainty distribution
created with a probabilistic sensi-
tivity analysis of 1,000 simulations
Ann Hematol (2010) 89:919–926 923
aconazole versus fluconazole decreased to €12,255 per LY
gained and €13,462 per QALY gained and the
corresponding probability of cost-effectiveness at a WTP
of €20,000 and €50,000 per QALY increased to 71% and
95%, respectively (Fig. 2).
When average first-line IFI treatment costs as reported
by Jansen et al. [5] were applied, the incremental costs of
posaconazole versus fluconazole slightly increased; how-
ever, the probability of cost-effectiveness remained similar.
Discussion
Cost-effectiveness analysis aims to provide information on
the expected costs and outcomes of a new intervention
relative to the accepted or standard intervention. When it is
said that an intervention is considered cost-effective, it does
not necessarily mean that the new treatment is cost-saving
relative to the standard intervention. The total costs
associated with the new treatment can be higher than with
the standard intervention and still be considered cost-
effective. This is the case if the new treatment significantly
enhances quality of life and/or life expectancy over and
above the current standard. The current cost-effectiveness
evaluation applies to the Dutch situation of prophylaxis of
invasive fungal infections among patients with GVHD.
Prophylaxis with posaconazole compared to fluconazole
resulted in a gain of 0.19 LYs and 0.17 QALYs
corresponding to €24,016 per LY gained and €26,225 per
QALY gained, respectively. This ICER reflects that
posaconazole can be considered cost-effective relative to
fluconazole in the Netherlands.
Analysis of alternative scenarios, such as fluconazole as
oral suspension, no discounting, and applying the first-line
IFI treatment costs as reported by Jansen et al. [5], resulted
in similar or improved cost-effectiveness estimates of
posaconazole relative to fluconazole. De Pauw et al.
commented that centers with a high incidence of invasive
aspergillosis are more likely to adopt antifungal prophylaxis
as a strategy [23]. In the trial of Ullmann et al., the authors
noted that the risk of contracting an IFI in their study was
lower than that reported in other studies, which could be
due to the fact that all patients in the Ullmann trial received
prophylaxis, and not all studies used the consensus criteria;
some studies included possible cases as well [11]. Conse-
quently, the background risk of contracting an IFI in the
clinical setting may be higher than the risk as reported by
Ullmann and used in the base-case analysis. Applying a
higher background risk of contracting an IFI (15%) reduced
the ICER of posaconazole to €13.462 per QALY, a more
favorable result.
The study was performed from the payer perspective,
which in this case is comparable to the societal perspective.
Since the patients considered were not employed due to the
severity of the underlying disease, indirect costs were not
included. Furthermore, costs for the underlying disease
were not included because the interest was in the additional
costs of prophylaxis and avoidance of IFIs.
In order to develop an economic model for antifungal
prophylaxis, several simplifications and assumptions were
made with respect to routine practice. An important
assumption is the application of survival as well as utility
estimates for chronic GVHD for patients that survived the
112-day prophylactic period. Although acute GVHD is an
important risk factor for chronic GVHD [24, 25], it is
unlikely that all of the acute GVHD patients from the
clinical trial by Ullmann et al. develop chronic GVHD [11].
Consequently, the life expectancy as well as the quality-of-
life of patients surviving the prophylactic period will be
underestimated and the cost-effectiveness as well. Further-
more, the Wingard data on survival originated from 1989;
the impact of any developments that improved care and
possibly survival since then were not taken into account
[14]. For the base-case scenario, it was assumed that the
prophylactic regimen did not affect the case fatality of an
IFI. Since the RCT conducted by Ullmann et al. reported a
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higher IFI case fatality for fluconazole than for posacona-
zole, the assumption of equal case fatality will bias against
posaconazole. Indeed, when treatment-specific IFI case
fatalities were applied, the cost per QALY gained almost
halved (€14,868).
For IFIs that occur despite prophylaxis, the current
model assumes similar IFI treatment costs for each
treatment arm. This assumption might result in a bias
favoring posaconazole prophylaxis, since “failures” on a
broad spectrum prophylactic agent, like posaconazole,
might be considered more complicated than those failing
on fluconazole prophylaxis. Consequently, patients who fail
on posaconazole might require treatment with more
expensive antifungal agents. However, since posaconazole
prophylaxis is not established, routine, practice data cannot
confirm this (expert opinion); therefore, similar IFI treat-
ment costs were assumed to reflect current clinical practice.
Efficacy of posaconazole versus fluconazole was
obtained from a RCT [11]. Although such a design provides
high quality of evidence, the actual estimates are still
characterized by (sampling) uncertainty (as represented by
95% confidence intervals). Utility and resource use data
used in the evaluation were extracted from other studies
than the Ullmann trial, adding additional uncertainty.
Model-based economic evaluations only provide value if
the uncertainties in the combination of different sources of
data are made explicit, and their impact is investigated.
Consequently, a PSA was conducted to quantify the
uncertainty in the expected costs, outcomes, and cost-
effectiveness based on the uncertainty in the source data.
For the base-case analysis, the probability of posaconazole
being cost-effective compared to fluconazole was only 32%
at a conservative WTP threshold of €20,000 per QALY.
However, in many countries including the Netherlands, the
WTP thresholds are not absolute limits, since the severity
of the disease is also a criterion that is considered [26–28].
Therefore, the WTP threshold for antifungal prophylaxis
can be expected to be considerably higher than €20,000 per
QALY. Using a WTP threshold of €50,000 or even €75,000
per QALY resulted in a higher probability of 79% and 89%,
respectively, that posaconazole prophylaxis is cost-effective
relative to fluconazole. A higher background risk for IFIs of
15% increased the probability of posaconazole being a cost-
effective option: a probability of 95% at a WTP level of
€50,000 per QALY was observed. Furthermore, IFIs can be
considered to pose a serious risk to the investments related
to HSCT. The estimated costs of €151,754 (1998 price
level) per patient for the first 2 years after transplantation,
should be considered when deciding on any WTP ratio
regarding cost-effectiveness for prophylaxis [29]. Although
the current analysis considered the official list prices of
antifungal drugs, actual acquisition cost of the drugs in a
hospital may of course differ. However, additional analysisTa
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demonstrated that differences in drug acquisition costs only
had a minor impact on the cost effectiveness (data not
shown).
Considering the medical necessity as well as the invest-
ments made for allogeneic HSCT, posaconazole can be
considered cost-effective relative to fluconazole for pro-
phylaxis of IFI in patients with GVHD in the Netherlands.
The cost-effectiveness of prophylactic posaconazole
depends on the IFI risk, which can vary by hospital.
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